# Chemoradiotherapy in Esophageal or Esophagogastric Junction Cancer

> **NCT04821778** · PHASE3 · RECRUITING · sponsor: **Cancer Institute and Hospital, Chinese Academy of Medical Sciences** · enrollment: 2000 (estimated)

## Conditions studied

- Esophagus Cancer
- Esophagogastric Junction Cancer
- Chemoradiation
- Targeted Therapy
- Immunotherapy
- Chemotherapy Effect

## Interventions

- **RADIATION:** Radiotherapy
- **DRUG:** Platinum based chemotherapy
- **DRUG:** Paclitaxel based chemotherapy
- **DRUG:** Immunotherapy
- **DRUG:** 5-FU Analog based chemotherapy
- **DRUG:** Nimotuzumab

## Key facts

- **NCT ID:** NCT04821778
- **Lead sponsor:** Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2002-01-01
- **Primary completion:** 2030-12-31
- **Final completion:** 2030-12-31
- **Target enrollment:** 2000 (ESTIMATED)
- **Last updated:** 2026-01-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04821778

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04821778, "Chemoradiotherapy in Esophageal or Esophagogastric Junction Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04821778. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*